Biliary tract cancers: topaz-1 up-date, a practice changing study
- PMID: 41383674
- PMCID: PMC12690302
- DOI: 10.21037/hbsn-2025-367
Biliary tract cancers: topaz-1 up-date, a practice changing study
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-367/coif). The authors have no conflicts of interest to declare.
Comment on
-
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources